Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, halted for about an hour...
looks like trading again ????? 'Mirna Therapeutics (MIRN)'
Halted for bid being at 5.70, outside price band. What was that?
nice chat/ nice action this morning/ Mirna Therapeutics C (MIRN)
6.37 ? 0.66 (11.56%)
Volume: 24,754 @ 11:31:23 AM ET
Bid Ask Day's Range
5.96 6.37 5.8 - 7.23
MIRN Detailed Quote Wiki
$MIRN slowly and steady up
Go $MIRN
Mirna Therapeutics C (MIRN) 5.67 ? 0.01 (0.18%)
Volume: 57,595 @ 3:59:58 PM ET
Bid Ask Day's Range
5.65 11.35 5.62 - 5.75
MIRN Detailed Quote Wiki
+++++/ MIRN
================================================
MIRN TWO YEAR CHART: NASDAQ
MIRN [-chart]charting.nasdaq.com/ext/charts.dll?2-1-14-0-0-524-03NA000000MIRN-&SF:6|8|27-SH:8=200|27=10-WD=539-HT=395-[/chart]
MIRN 10yr, Chart NASDAQ
MIRN [-chart]charting.nasdaq.com/ext/charts.dll?2-1-14-0-0-5120-03NA000000MIRN-&SF:1|39|38|8|27-SH:8=20|27=10-WD=539-HT=395-[/chart]
http://www.barchart.com/quotes/stocks/MIRN
MIRN [-chart]www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=MIRN&size=analysis&support=0.00,15,0.00,66,0.00,38,0.00,14,0.00,12,0.00,15,0.00,3,0.00,2,0.00,4,0.00,6,0.00,2&trend=[/chart]
+++++/ MIRN [-chart]www.stockscores.com/chart.asp?TickerSymbol=MIRN&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
================================================
Mirna Therapeutics C (MIRN)
5.68 ? 0.02 (0.35%)
Volume: 56,079 @ 3:35:01 PM ET
Bid Ask Day's Range
5.68 5.7 5.62 - 5.75
MIRN Detailed Quote Wiki
thank you,
re;
They are a new IPO only since Oct 1. This is their business...
MIRN is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.
microRNAs are naturally occurring, short ribonucleic acid, or RNA, molecules, or oligonucleotides, that play a critical role in regulating key biological pathways.
Misexpression of even a single microRNA can contribute to disease development and tumor suppressor microRNAs are commonly reduced in cancer.
MIRN's scientists and others at leading academic institutions have identified numerous tumor suppressor microRNAs that play key roles in preventing normal cells from becoming cancerous and facilitating proper cancer immunosurveillance.
To enable therapeutic application of these tumor suppressor microRNAs, MIRN pioneered technologies for creating RNA molecules that function as natural microRNAs when they enter human cells.
re;
Thanks mick... Peacefulwendy Mirna Therapeutics 10/22/2015 06:22:49 PM
They are a new IPO only since Oct Peacefulwendy Mirna Therapeutics 10/22/2015 06:21:26 PM
you are welcome, interesting biotech one.
you have any updates ?????
My pleasure
Go $MIRN
Thanks Pete... Very nice...
Just quickly build the Intro-Page for MIRN. I will spend little bit more time later to refine tune them later
Go $MIRN
They are a new IPO only since Oct 1. This is their business...
MIRN is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. microRNAs are naturally occurring, short ribonucleic acid, or RNA, molecules, or oligonucleotides, that play a critical role in regulating key biological pathways.
Misexpression of even a single microRNA can contribute to disease development and tumor suppressor microRNAs are commonly reduced in cancer.
MIRN's scientists and others at leading academic institutions have identified numerous tumor suppressor microRNAs that play key roles in preventing normal cells from becoming cancerous and facilitating proper cancer immunosurveillance.
To enable therapeutic application of these tumor suppressor microRNAs, MIRN pioneered technologies for creating RNA molecules that function as natural microRNAs when they enter human cells.
Mirna rallies major players for $42M round, hits the gas in immuno-oncology
April 30, 2015 | By Damian Garde
Mirna Therapeutics hauled in a $41.8 million D round to get its RNA treatment into Phase II trials, assembling a big-name syndicate to back its ambitions in immuno-oncology.
Baxter Ventures ($BAX) led the Austin biotech's latest round, joined by new backers including Celgene ($CELG) and Morningside, and a group of repeat investors featuring New Enterprise Associates, Pfizer ($PFE), Sofinnova Ventures and others.
Mirna has earmarked its latest cash for MRX34, a micro-RNA treatment designed to mimic a naturally occurring tumor suppressant that helps the immune system better attack cancerous growth. The treatment is currently in an open-label Phase I trial, charting a dose-dependent effect on key oncogenes in interim results presented at this month's American Association for Cancer Research.
DATE: TUESDAY, NOVEMBER 10TH | 11AM ET / 8AM PT
The next revolution in clinical trial execution is taking shape in the rapid adoption of mHealth technologies. PPD experts discuss how current PPD-conducted studies assess the feasibility of wearable data collection devices in trials to achieve focused endpoints and improve the patient experience. Register Now!
Sign up for our FREE newsletter for more news like this sent to your inbox!
Now the biotech is planning to roll MRX34 into a Phase Ib study with eyes on kicking off Phase II next year. Mirna plans to nail down an ideal indication for the treatment once it has final results from the Phase I study, which is examining the drug's effect on hepatocellular carcinoma, other solid tumors and hematological malignancies. The latest fundraise will also allow Mirna to get a second, undisclosed microRNA treatment into the clinic and mount a combination therapy program, the company said.
The microRNA field has long been fraught with setbacks and safety concerns, but investors have warmed up to the prospect in recent years. And Mirna, billing itself as a leader in the space, believes the future is bright for microRNA therapies.
"This successful financing further demonstrates the enthusiasm of the investment community for the Mirna opportunity and is an important validation of the therapeutic potential of our differentiated microRNA replacement therapy approach," CEO Paul Lammers said in a statement.
Mirna's round comes nearly three years after Mirna banked $34.5 million in Series C funds, cash that helped the biotech get its top prospect into the clinic in 2013.
http://www.fiercebiotech.com/story/mirna-rallies-some-major-players-418m-round-hitting-gas-immuno-oncology/2015-04-30
Mirna Therapeutics MIRN/ Sun, 04 Oct 2015 13:25:30 GMT ~ 10 IPOs on Calendar for Week Ahead
read full: http://247wallst.com/investing/2015/10/04/10-ipos-on-calendar-for-week-ahead/
*********************************************************
Fri, 02 Oct 2015 05:00:01 GMT ~ U.S. IPO market seen shaken but not shut
[Reuters] - Many companies gearing up for initial public offerings in the United States are expected to stick with their plans despite a wave of discounted pricings this week, though the size of their stock sales could be cut, industry experts said on Thursday.
Four companies announced offering prices below the expected range this week, the first string of IPO pricings since the stock market plummeted in August.
The CBOE volatility index, essentially Wall Street's 'fear gauge,' has recently lingered above the 20 mark, which many IPO investors view as the threshold between an open and a treacherous IPO landscape.
read full: http://finance.yahoo.com/news/u-ipo-market-seen-shaken-050001915.html
*********************************************************
Thu, 01 Oct 2015 20:07:03 GMT ~ Austin biotech company makes Wall Street debut
read full: http://www.bizjournals.com/austin/news/2015/10/01/austin-biotech-company-sees-gains-in-wall-street.html?ana=yahoo
*********************************************************
'Mirna Therapeutics (MIRN)' trade in A.H. TRADING/
'Mirna Therapeutics (MIRN)'
MIRN IPOs 7.19M* shares @$7.00: 'Mirna Therapeutics (MIRN)'
http://finance.yahoo.com/news/mirna-therapeutics-announces-pricing-initial-110000269.html
Quote:
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer.
Mirna’s lead product candidate,
MRX34, a mimic of naturally occurring microRNA-34 (miR-34),
is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer,
advanced solid tumors and hematological malignancies.
miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways,
with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1.
The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance.
Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents.
The company was founded in 2007 and is located in Austin, Texas.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117385445&txt2find=mirn
http://investorshub.advfn.com/Biotech-Values-1418/
i gathering some for the forum/ NEWS 10-06-15/ PUBLIC OFFERING/ [MIRN Mirna Therapeutics 6 3 minutes ago Medical - Drugs
http://investorshub.advfn.com/Mirna-Therapeutics-MIRN-30360/
http://investorshub.advfn.com/boards/getboards.aspx?searchstr=mirn
http://investorshub.advfn.com/Mirna-Therapeutics-MIRN-30360/
no mods
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company who develops microRNA-based oncology therapeutics.
========================================================
Tue, 06 Oct 2015 15:54:07 GMT ~ Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
[at noodls] - Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
read full: http://www.noodls.com/view/A24A0CE01ABE4A5981099847387E346D31586963
*********************************************************
Tue, 06 Oct 2015 15:11:00 GMT ~ Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
[Business Wire] - Mirna Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $7.00 per share.
read full: http://finance.yahoo.com/news/mirna-therapeutics-announces-closing-initial-151100306.html
*********************************************************
Sun, 04 Oct 2015 13:25:30 GMT ~ 10 IPOs on Calendar for Week Ahead
read full: http://247wallst.com/investing/2015/10/04/10-ipos-on-calendar-for-week-ahead/
*********************************************************
Fri, 02 Oct 2015 05:00:01 GMT ~ U.S. IPO market seen shaken but not shut
[Reuters] - Many companies gearing up for initial public offerings in the United States are expected to stick with their plans despite a wave of discounted pricings this week, though the size of their stock sales could be cut, industry experts said on Thursday. Four companies announced offering prices below the expected range this week, the first string of IPO pricings since the stock market plummeted in August. The CBOE volatility index, essentially Wall Street's 'fear gauge,' has recently lingered above the 20 mark, which many IPO investors view as the threshold between an open and a treacherous IPO landscape.
read full: http://finance.yahoo.com/news/u-ipo-market-seen-shaken-050001915.html
*********************************************************
Thu, 01 Oct 2015 20:07:03 GMT ~ Austin biotech company makes Wall Street debut
read full: http://www.bizjournals.com/austin/news/2015/10/01/austin-biotech-company-sees-gains-in-wall-street.html?ana=yahoo
*********************************************************
do you have much information for MIRN thank you for establishing this forum.
$MIRN ~ Mirna Therapeutics, Inc. due diligence report
$MIRN recent news/filings
## source: finance.yahoo.com
Tue, 06 Oct 2015 15:54:07 GMT ~ Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
[at noodls] - Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
read full: http://www.noodls.com/view/A24A0CE01ABE4A5981099847387E346D31586963
*********************************************************
Tue, 06 Oct 2015 15:11:00 GMT ~ Mirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT
[Business Wire] - Mirna Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $7.00 per share.
read full: http://finance.yahoo.com/news/mirna-therapeutics-announces-closing-initial-151100306.html
*********************************************************
Sun, 04 Oct 2015 13:25:30 GMT ~ 10 IPOs on Calendar for Week Ahead
read full: http://247wallst.com/investing/2015/10/04/10-ipos-on-calendar-for-week-ahead/
*********************************************************
Fri, 02 Oct 2015 05:00:01 GMT ~ U.S. IPO market seen shaken but not shut
[Reuters] - Many companies gearing up for initial public offerings in the United States are expected to stick with their plans despite a wave of discounted pricings this week, though the size of their stock sales could be cut, industry experts said on Thursday. Four companies announced offering prices below the expected range this week, the first string of IPO pricings since the stock market plummeted in August. The CBOE volatility index, essentially Wall Street's 'fear gauge,' has recently lingered above the 20 mark, which many IPO investors view as the threshold between an open and a treacherous IPO landscape.
read full: http://finance.yahoo.com/news/u-ipo-market-seen-shaken-050001915.html
*********************************************************
Thu, 01 Oct 2015 20:07:03 GMT ~ Austin biotech company makes Wall Street debut
read full: http://www.bizjournals.com/austin/news/2015/10/01/austin-biotech-company-sees-gains-in-wall-street.html?ana=yahoo
*********************************************************
$MIRN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$MIRN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MIRN/company-info
Ticker: $MIRN
OTC Market Place: Not Available
CIK code: not found
Company name: Mirna Therapeutics, Inc.
Incorporated In:
Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:24,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:11,2:10,3:8,4:12,5:3,6:25,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){if(window.addEventListener){var e=t("handle"),n=t("ee");t(1),window.addEventListener("click",function(){e("inc",["ck"])},!1),window.addEventListener("hashchange",function(){e("inc",["hc"])},!1),n.on("pushState-start",function(){e("inc",["ps"])})}},{1:9,ee:"QJf3ax",handle:"D5DuLP"}],6:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],7:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3);var a=Event;n.on("fn-start",function(t){var e=t[0];e instanceof a&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof a&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:11,2:10,3:9,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],8:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=t("ee").create(),i=t(1)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t,e){function n(){return s}if(t[1]){var r=t[1];if("function"==typeof r){var s=a(r,"nr@wrapped",function(){return i(r,"fn-",n,r.name||"anonymous")});this.wrapped=t[1]=s,o.emit("initEventContext",[t,e],this.wrapped)}else"function"==typeof r.handleEvent&&i.inPlace(r,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:26,ee:"QJf3ax",gos:"7eSDFh"}],9:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState","replaceState"],"-")},{1:26,ee:"QJf3ax"}],10:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:26,ee:"QJf3ax"}],11:[function(t,e){function n(t,e,n){t[0]=i(t[0],"fn-",null,n)}function r(t,e,n){function r(){return a}this.ctx={};var a={"nr@context":this.ctx};o.emit("initTimerContext",[t,n],a),t[0]=i(t[0],"fn-",r,n)}var o=t("ee").create(),i=t(1)(o);e.exports=o,i.inPlace(window,["setTimeout","setImmediate"],"setTimer-"),i.inPlace(window,["setInterval"],"setInterval-"),i.inPlace(window,["clearTimeout","clearImmediate"],"clearTimeout-"),o.on("setInterval-start",n),o.on("setTimer-start",r)},{1:26,ee:"QJf3ax"}],12:[function(t,e){function n(){f.inPlace(this,p,"fn-",o)}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),e.hasOwnProperty("addEventListener")&&u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:8,2:26,ee:"QJf3ax"}],13:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1),u=window.XMLHttpRequest;t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof u&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:14,3:12,4:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],14:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],15:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:24,2:25,handle:"D5DuLP"}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):void(r.q&&(r.q[t]||(r.q[t]=[]),r.q[t].push(e)))}var r=t("ee").create();e.exports=n,n.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=window,f=c.document;t(2);var u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-768.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:24,2:15,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],24:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],25:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r
$MIRN share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$MIRN extra dd links
Company name: Mirna Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MIRN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MIRN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MIRN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/news - http://finance.yahoo.com/q/h?s=MIRN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MIRN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MIRN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MIRN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Mirna+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Mirna+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Mirna+Therapeutics%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MIRN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MIRN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MIRN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MIRN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MIRN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MIRN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MIRN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MIRN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MIRN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MIRN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MIRN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MIRN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MIRN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MIRN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MIRN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MIRN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MIRN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MIRN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MIRN
$MIRN IPO Preview: Mirna Therapeutics
http://seekingalpha.com/article/3542656-ipo-preview-mirna-therapeutics
$MIRN Mirna Therapeutics: A Healthy IPO To Start The Week
http://seekingalpha.com/article/3538246-mirna-therapeutics-a-healthy-ipo-to-start-the-week
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
84
|
Created
|
10/20/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |